Who was studied, and how
One number in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 23 other studies
138people with obesity, in this paper
The trial randomly assignedassigned by chance
teneligliptin 20 mg plus canagliflozin 100 mg (T+C)
teneligliptin 20 mg plus placebo (T+P)
Reported lower HbA1c change from baseline to week 24, no range given−0.88
randomisedthe abstract, start to end
… change from baseline to week 24 was -0.88% (least-squares mean, …
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
HbA1c change from baseline to week 24teneligliptin 20 mg plus canagliflozin 100 mg (T+C) vs teneligliptin 20 mg plus placebo (T+P)
−0.88
SGLT2 inhibitorsDPP-4 inhibitorsGlycemic control
DPP-4 inhibitors × glycemic controlhelps?replicated
unlikelylikely
0.820.82 without it
SGLT2 inhibitors × glycemic controlhelps?replicated
unlikelylikely
0.920.92 without it
← favours treatmentfavours comparator →
1 / 6